A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma
← catalyst calendarSponsored by Genenta Science (industry) · GNTA — their whole pipeline →. With Alira Health, Arithmos srl, Ospedale San Raffaele.
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Persistent challenges have been encountered in patient recruitment, difficulty in identifying a sufficient number of eligible subjects. The decision to terminate the study was not based on any safety concerns. Benefit-risk profile of IP unchanged.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-22 | actual | When the study began enrolling |
| Primary completion | 2026-01-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-23 | actual | The whole study's end, after follow-up |
| First posted | 2024-12-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Clear Cell RCC
Interventions
- Genetic: Temferon
- Biological: Pembrolizumab
- Drug: Cabozantinib
Primary outcomes
what the primary-completion date above is the date OFPermalink · GNTA's whole pipeline · Catalyst calendar · Every registered study · What changed